Login
Register
My Saved
My Account
Cart (
)
Log Out
My Saved
Topics
Immunology and Biologics
All of Immunology and Biologics
Comparative Safety and Efficacy
Emerging Therapies
Immunology: Targets and Treatments
Mechanisms of Autoimmunity
Treatment Initiation and Monitoring
Osteoarthritis
Lupus
Rheumatoid Arthritis
Editorial Board
Educational Tools
Self-Assessment
Toggle navigation
Immunology and Biologics
All of Immunology and Biologics
Comparative Safety and Efficacy
Emerging Therapies
Immunology: Targets and Treatments
Mechanisms of Autoimmunity
Treatment Initiation and Monitoring
Osteoarthritis
Lupus
Rheumatoid Arthritis
Editorial Board
Educational Tools
Self-Assessment
Educational Tools
Educational Tools For Your Clinical Practice
Educational Tool Spotlight
Whiteboard: Differentiating COVID-19 and Influenza – From Transmission to Treatment
For additional downloadable handouts and online resources, visit below.
Biosimilars
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
Biosimilars: implications for rheumatoid arthritis therapy.
The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
Clinical trials of biosimilars should become more similar.
Biosimilars: More Treatment Options Are on the Way
FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
Giant Cell Arteritis
Giant Cell Arteritis – Fast Facts for Patients
Giant Cell Arteritis – Vasculitis Foundation
ACR Classification of Giant Cell Arteritis
Recognition and Management of Giant Cell Arteritis
GIACTA Trial of Tocilizumab in Giant Cell Arteritis
Giant Cell Arteritis
Gout
Treat to target in gout
Immune-mediated adverse reactions
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline
The management of immune-related adverse events associated with immune checkpoint blockade
The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy
Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
Spondyloarthritis
What Is Axial Spondyloarthritis (AxSpA)?
Recommendations for the Treatment of Ankylosing Spondylitis
Juvenile Idiopathic Arthritis (JIA)
ACR Update of Recommendations to the Treatment of JIA
What is JIA? - Patient Handout
Rheumatoid Arthritis (RA)
RA and Vaccinations
JAK Inhibitors for Rheumatoid Arthritis
IL-6 Inhibitors for Rheumatoid Arthritis
TNF-alpha inhibitors for Rheumatoid Arthritis
RA Treat-to-Target Recommendations
The Purple Book for Biosimilars
2015 ACR Guideline for the Treatment of RA
RA Overview (for Patients)
RA Treatment (for Patients)
Biologic-free Remission in Established RA
EULAR Recommendations Update: Management of RA
RA Drug Guide: Analgesics, Steroids, Biologics, DMARDs, NSAIDs - For Patients
×
Close
Notice